Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Prolixin brand and generic had U.S. sales of approximately $134 million MAT for the most recent twelve months ending in December 2020 according to IQVIA Health*.

Dr. Reddy's Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4594 as compared to the previous close of Rs. 4696. The total number of shares traded during the day was 21208 in over 2332 trades.

The stock hit an intraday high of Rs. 4704.1 and intraday low of 4580. The net turnover during the day was Rs. 98072065.

Source : Equity Bulls

Keywords